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Abstract
Chronic infection of the respiratory tract is a hallmark of cystic ﬁbrosis (CF). Antibiotic treatment has been used as one of the mainstays
of therapy and together with other treatment modalities has resulted in increased survival of CF patients. Increasing resistance of CF-speciﬁc
pathogens to various classes of antibiotics explains the need for novel antibiotic strategies. This review focuses on the future development
of new antibiotic therapies, including: (1) New targets, (2) novel antibiotic regimens in CF, (3) new antibiotics, and (4) other investigational
therapies. In addition, we brieﬂy summarize developments in the area of microbial diagnostics and discuss interactions between the complex
pulmonary microﬂora.
© 2011 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
The projected life expectancy of individuals with cystic ﬁ-
brosis (CF) has increased signiﬁcantly during the last 20 years
and is expected to be >50 years for individuals born in 2000
[1]. The development of novel antibiotic drugs and therapeutic
regimens has contributed greatly to advances in the treatment
of CF patients [2]. However, these improvements are lim-
ited by several factors: (1) Chronic infection with typical
CF-speciﬁc microorganism cannot be cured and pulmonary
infectious disease still causes the majority of mortality and
morbidity in CF. (2) The interaction between the host and
pathogens is complex in CF lung disease. Young patients
are often infected with Haemophilus spp. and Staphylococcus
aureus. Subsequently, Pseudomonas aeruginosa becomes the
predominant pathogen. Burkholderia cepacia complex and
Stenotrophomonas maltophilia also infect CF airways [3].
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These and other bacteria adapt to the CF-speciﬁc environ-
ment. In addition to the broad antibiotic resistance of some of
these microorganisms, bioﬁlm formation and the development
of cellular resistance mechanisms, such as the induction of ef-
ﬂux pumps, attenuates the effectiveness of antibiotic therapy.
Multidrug resistance (MDR) is a clinically relevant problem.
While this review focuses on bacterial infection, fungal and
viral infections are recognized as clinically relevant to the
development of CF lung disease [4].
2. New diagnostic approaches
2.1. Analysis of emerging pathogens and of the CF
microbiome
The bacteria most frequently isolated from the sputum
of patients with CF such as S. aureus, non-capsulated
H. inﬂuenzae and P. aeruginosa are identiﬁed by stan-
dard aerobic microbiological methods. Moreover, individuals
with CF are susceptible to chronic respiratory tract in-
fection with fast-growing mycobacteria and gram-negative
bacterial species that are intrinsically resistant to a broad
range of antimicrobial agents and usually are poor air-
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way colonizers and not pathogenic for healthy persons.
These emerging and/or rare CF pathogens include Mycobac-
terium chelonae, Mycobacterium abscessus, Streptococcus
spp., Stenotrophomonas maltophilia, Achromobacter (Alcali-
genes) xylosoxidans, Inquilinus limosus and several species
within the genera Burkholderia, Ralstonia and Pandoraea.
The majority of these species are not included in automated
identiﬁcation systems. Hence, deﬁnitive diagnosis requires
16S rDNA sequencing and thorough expertise in CF microbi-
ology. Recent culture-independent DNA-based proﬁling of CF
respiratory secretions uncovered a further layer of complexity
of CF microbiology [5,6]. The bacterial community within the
CF lung was found to be polymicrobial in nature including
a range of anaerobic species primarily within the genera
Prevotella, Veillonella, Propionibacterium and Actinomyces
[7,8]. Although the clinical relevance of anaerobic bacteria for
CF lung infection is an open question, we can envision that
CF microbiology will soon become much more complex than
the routine clinical microbiology than it is now.
2.2. Sampling of upper and lower CF airways
Besides the ever-growing list of CF-associated bacterial
pathogens, the modes of sampling have recently re-emerged
as a timely issue of CF diagnostic microbiology. How many
samples should be collected from which site by applying
which technique? Typically, just one throat swab, sponta-
neously expectorated sputum sample or induced sputum will
be processed at the patient’s visit to the CF clinic. However,
according to culture-independent 16S rDNA proﬁling a single
expectorated or induced sputum sample represents only ap-
proximately 60% of the bacterial species found through the
comprehensive analysis of ﬁve samples collected in series on
the same day [9]. These data suggest that sampling in greater
depth may be a more effective strategy. It remains to be seen
whether such a procedure is practically feasible for routine
patient care.
Sputum bacteriology is taken as a surrogate for the
microbial colonisation of the lower airways. The microbiome
of the upper airways is usually not assessed. A recent study
challenges this attitude [10]. The authors sampled the upper
airways of CF patients by nasal lavage. They found identical
S. aureus and P. aeruginosa genotypes colonising the upper
and lower airways of CF patients [10]. This result suggests
that the upper airways are a gateway for the acquisition
of common CF pathogens and act as a reservoir for them.
Because nasal lavage requires training and active cooperation,
it is not applicable to all age groups. However, it is sufﬁciently
rapid and easy to become widely introduced into the clinic.
2.3. Assessment of clonal variants
A further characteristic feature of CF isolates that im-
pedes the straightforward identiﬁcation of taxa is their broad
spectrum of numerous and often atypical phenotypes. Mor-
photypes of a single clone may differ substantially in their
antimicrobial susceptibility. Of particular signiﬁcance for
antimicrobial treatment are small colony variants [11] and hy-
permutable strains [12] that often confer multidrug-resistant
phenotypes to the polymicrobial community of CF lungs.
Hence, the presence of these phenotypic variants in bacterio-
logical specimens and their antimicrobial susceptibility should
be communicated to the CF physician.
A further challenge is the different lifestyle of the microbes
in the CF lungs that either may thrive in the planktonic state
or may be embedded in intraluminal bioﬁlms [13]. Standard
susceptibility testing assesses the effect of antimicrobial
drugs on planktonic bacteria in the late exponential or early
stationary growth phase. Hence, in vitro tests mimic only
part of the microbial community in CF airways. However,
this deﬁcit has been recognized by researchers who set up
protocols for susceptibility testing of bioﬁlm-grown pathogens
such as the Calgary Bioﬁlm Device [14] or a bacterial viability
stain in combination with automated confocal laser scanning
microscopy [15].
3. Novel antibiotic regimens in CF
As chronic P. aeruginosa infection is one of the major fac-
tors contributing to progressive deterioration of lung function
in CF patients, pulmonary exacerbations due to P. aerugi-
nosa are treated with IV antibiotics, mostly combinations of
a beta-lactam, such as ceftazidime, and an aminoglycoside,
such as tobramycin. In conventional treatment regimens, both
antibiotics are administered in the form of thrice-daily short
infusions, but new treatment regimens are sought to decrease
toxicity and improve efﬁciency, especially as multiple drug
resistance develops. Aminoglycosides have concentration-
dependent antibacterial activity and a post-antibiotic effect,
whereas beta-lactam antibiotics display time-dependent an-
tibacterial activity. Once daily tobramycin provides a greater
peak concentration that improves efﬁcacy while reducing
overall exposure to the drug and hence, decreasing the risk
of toxicity. Efﬁcacy was shown to be comparable for once
and thrice-daily dosing of tobramycin in CF [16]. Although
decreased nephrotoxicity was demonstrated only in non-CF
patients, the US CF Foundation recommends once-daily dos-
ing of aminoglycosides to avoid the risk of toxicity [17].
There are limited clinical data about the toxicity of contin-
uous ceftazidime infusions in CF patients, but recent studies
demonstrate that continuous infusion does not increase drug
toxicity and appears to be as effective as short infusions. Im-
portantly, continuous ceftazidime infusions give better results
in CF patients harboring resistant isolates of P. aeruginosa
[18]. Such a treatment regimen for IV antibiotics might also
facilitate treatments when they take place at home, making
it possible for the nurse to visit the patient only once per
day. It also allows patients to continue to attend school
or work if their general status permits during IV antibiotic
treatment.
Outcomes in CF patients with chronic pulmonary Pseu-
domonal infection can be improved by the daily use of neb-
ulized anti-Pseudomonal antibiotics, especially tobramycin.
However, long nebulization times may adversely impact on
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adherence to the treatment regimen. New nebulizers are
expected to reduce drug nebulization times. For example,
delivery of tobramycin solution for inhalation (TSI) via
the PARI eFlow® rapid nebulizer (PARI GmbH, Starnberg,
Germany) is quicker (e.g. ∼4 min) than the same dose of
TSI administered via the Pari LC® PLUS nebulizer (PARI
GmbH) powered by the DeVilbiss Pulmo-Aide® compressor
(DeVilbiss, Philadelphia, USA) (e.g. ∼15 min). The systemic
exposure and sputum concentration of tobramycin from eFlow
rapid and LC PLUS appear to be broadly similar [19].
Prevention of chronic P. aeruginosa infection by antibiotic
therapy initiated shortly after developing a new P. aeruginosa
infection is part of the standard care of CF patients. It is
usually effective, but the optimal therapeutic regimen and
duration for early treatment remains unclear. The EarLy
Inhaled Tobramycin for Eradication (ELITE) study has been
conducted in 98 CF patients (aged ≥6 months) with early
P. aeruginosa infection to assess the efﬁcacy and safety of two
regimens (28 and 56 days) of TSI (TOBI®) [20]. It concluded
that TOBI® twice daily for 28 days is as effective as 56 days
and well tolerated therapy for early P. aeruginosa infection in
CF patients.
The results of the EPIC (Early Pseudomonas Infection
Control) clinical trial were presented at the 2009 North
American Cystic Fibrosis Conference [21]. The study enrolled
304 children with CF aged 1 to 12 years to evaluate
early intervention with inhaled and oral anti-Pseudomonal
therapy at ﬁrst isolation of P. aeruginosa from respiratory
cultures. Two different antimicrobial treatment regimens were
investigated: (1) culture-based therapy (i.e. treatment based on
microbiological ﬁndings of P. aeruginosa positive respiratory
cultures) and (2) cycled antibiotic therapy (i.e. treatment
provided systematically in quarterly cycles until the end of the
18-month study period). Inhaled tobramycin was associated
with oral ciproﬂoxacin or with placebo. No difference was
observed between the treatment groups in the proportion of
recurrent P. aeruginosa positive cultures, in time to pulmonary
exacerbation requiring antibiotics or in other measures of
clinical efﬁcacy (change in mean weight or in mean FEV1
from baseline) [21].
Besides antibiotic treatment for P. aeruginosa, particular
attention should be paid to patients colonized with methicillin
resistant S. aureus (MRSA). Although there is less clinical
evidence than for eradication of P. aeruginosa, eradication
of MRSA is achievable in the majority of patients even
when signiﬁcant time has lapsed from initial isolation. In
some instances, up to 3 courses of antibiotics were required
to achieve eradication [22]. The most frequent regimens
included linezolid or rifampicin in association with fucidin,
trimethoprim or doxycycline.
4. Antibiotics in the pipeline
The anti-infective therapeutics pipeline contains mainly
new inhaled formulations of existing antibiotics to improve
delivery times, which will facilitate adherence to treatment.
The pipeline also contains antibiotics with different mecha-
nisms of action against P. aeruginosa and other CF pathogens
to improve their efﬁcacy.
Aztreonam lysine for inhalation (AZLI) is now available
to CF patients. It was evaluated in 246 CF patients (>6
years) on maintenance treatment for P. aeruginosa airway
infection in a randomized, double-blind, placebo controlled
study [23]. Patients were treated with 75 mg AZLI or placebo,
twice or three times daily for 28 days and then monitored
for 56 days. AZLI treatment delayed the time until inhaled
or IV anti-Pseudomonal antibiotics were required, improved
respiratory symptoms and pulmonary function and was well
tolerated.
New drug formulations have appeared, such as Tobramycin
Inhalation Powder (TIP), a novel dry-powder formulation
designed to deliver a high dose of tobramycin topically
to the lungs for management of chronic P. aeruginosa
infections. Serum tobramycin pharmacokinetics (PK) proﬁles
were similar for TIP and TSI. Four capsules of 28 mg
TIP (total tobramycin dose 112 mg) produced comparable
systemic exposure to 300 mg TSI, in less than one-third of
the administration time. The most common adverse events
associated with TIP were cough and dysgeusia [24]. The
results of a phase 3 study are expected shortly.
Inhalable dry powder is also being developed for
ciproﬂoxacin, alone or in association with recombinant de-
oxyribonuclease [25]. Co-delivery of antibiotics and DNase
using an inhalable particle system may be a promising strategy
for local anti-Pseudomonal therapy in CF airways.
Arikace™ is a sustained-release lipid formulation of
amikacine for inhalation, delivered in 10–13 minutes by
Pari eFlow® [26]. In a phase 2 study, Arikace™ administered
once daily for 28 days was well tolerated. Patients receiving
Arikace™ had superior clinical beneﬁt and prolonged time to
exacerbation as compared to placebo. Patients receiving 560
mg of Arikace™ demonstrated improvement in lung function
over baseline while patients on placebo declined over time. A
treatment effect of 14% of FEV1 % predicted was observed at
two months after discontinuing study drug.
Liposome entrapment of other antibiotics, such as to-
bramycin and polymixin B, may be a promising therapeutic
strategy for CF lung infections. This formulation reduces an-
tibiotic inhibition up to 100-fold and the colony-forming units
(CFU) of endogenous P. aeruginosa in sputum by 4-fold com-
pared to the conventional antibiotic [27]. Liposomes are often
used to improve the pharmaceutical preparation of lipophilic
substances and are also known to increase penetration into
bioﬁlms [28]
Aerosolized levoﬂoxacin is more potent than aminogly-
cosides and aztreonam against P. aeruginosa bioﬁlms. High
concentrations of levoﬂoxacin readily achievable in the lung
following aerosol delivery might be useful for the manage-
ment of pulmonary infections in CF patients [29].
Finally, a new anti-Pseudomonal cephalosporin, CXA-101,
seems promising for patients with CF, bettering the activity
of ceftazidime against resistant P. aeruginosa strains and
retaining activity against those with carbapenem resistance
[30].
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5. Novel microbial targets
Novel microbial targets are urgently needed to overcome
rising antibiotic resistance of important human pathogens.
However, evidence from previous antimicrobial screenings,
in silico analysis, and experimental target evaluation suggests
that the number of novel bacterial targetsmight be severely lim-
ited [31]. An exhaustive screening in enterobacteria, for exam-
ple, revealed that the targets, which were identiﬁed to be essen-
tial for the bacterial cell almost all belonged to metabolic path-
ways that are inhibited by current antibiotics or that have pre-
viously been considered for antimicrobial development [32].
Current research projects in the ﬁeld of antimicrobial
treatment of bacterial infections in CF screen small molecule
libraries, design antisense nucleic acids or investigate an-
timicrobial peptides for their activity against typical CF
pathogens. Adhesins [33] and the c-di-GMP signalling net-
work [34] are discussed as novel targets for antimicrobial
treatment. An active ﬁeld is the search for quorum-sensing in-
hibitors [35,36]. Based on experience in Japan on the efﬁcacy
of long-term treatment of chronic P. aeruginosa pulmonary
infections with azithromycin [37], this well-known macrolide
was recently introduced into the CF clinic. One major mode
of its multiple actions is the inhibition of quorum sensing
[38]. Thus, drugs that have been in clinical use for many years
are being re-evaluated as beneﬁcial agents for antimicrobial
therapy in CF. Other examples are the increasing use of sys-
temic colistin that disrupts the gram-negative inner membrane
for the treatment of multi-resistant P. aeruginosa [39] or
systemic temocillin, a 6-(α)-methoxy-carboxypenicillin with
exceptional stability in the presence of most β-lactamases, for
the treatment of pulmonary infections with the B. cepacia
complex [40].
6. Phage-based antibacterial therapy
Phage-based therapies are based on the natural interaction
between (bacterio-)phages and their host, the bacterial cell.
Lytic phages kill their bacterial host following ampliﬁcation
and release progeny phages [41]. The possibility of applying
the bacteriolytic activity of phages to treat infections was rec-
ognized as early as the 1920s [42]. Several non-randomized
studies claimed efﬁcacy, however, the quality of many of these
studies was low. Potential advantages are: (1) phage-based
therapies would be complementary to classical antibiotic ap-
proaches, (2) current data indicate low toxicity, (3) bacterial
strains resistant to known antibiotics might be susceptible
to phage based therapies. Obstacles to phage-based therapies
include the narrow host range of an individual phage. To
overcome this problem, many studies have been performed
with phage cocktails with multiple components. This will
cause problems with drug approval by drug regulation author-
ities. The principle of phage therapy is also not patentable,
resulting in difﬁculties protecting intellectual property and
dissuading investment in this area. While some groups and
small companies work in this direction, the translation into
clinical medicine appears difﬁcult.
7. Augmentation of the immune system
The modulation of immunity is an intriguing concept for
treatment of CF lung disease. However, it is difﬁcult to
achieve due to the complexity of the interactions between
host and microbe. Inﬂammation in CF lung disease is largely
caused by the recognition of bacterial structures by pattern
recognition receptors such as Toll-like receptors (TLRs).
Therapeutic targeting of innate immunity with TLR agonists
and antagonists might allow increasing antibacterial activity
and decrease inﬂammatory responses [43].
The protease/antiprotease system interaction with several
inﬂammatory cascades is severely dysregulated in CF lung
disease. Supplementation of alpha-1-antitrypsin resulted in
increased bacterial killing in a preclinical model [44] as well
as in CF clinical trial [45].
Vitamin D (VitD) has multiple activities in addition to its
regulatory role in calcium homeostasis. Importantly, it is now
recognized that VitD regulates the immune system, impacting
on many cell types of the adaptive and innate immune systems
[46]. In macrophages [47] and airway epithelial cells [48],
VitD derivates increase antibacterial activity and modulate
inﬂammation.
In experimental systems, the immune system can also be
modulated to either increase antimicrobial activity or decrease
inﬂammation. For example, pretreatment with inactivated
Hemophilus protected a murine model of infection against
death [49,50]. Also the modulation of TLRs can be applied in
experimental systems to modulate inﬂammation [43].
8. Summary
The exact mechanisms that link mutations in the cystic
ﬁbrosis transmembrane conductance regulator (CFTR) with
infectious lung disease in CF are unknown. However, devel-
opment of antibiotic therapy is the most important reason for
improvements in the prognosis of individuals with CF. Novel
developments in antibiotic therapy include the detection of
(a limited number of) new targets, the development of new
antibiotics, and the evaluation of the clinical use of novel
regimens. One current focus is topically, inhaled antibiotics.
While this appears promising, the likelihood is that there
will be a limited number of new antibiotics available in the
next few years, especially for gram-negative bacteria [51].
Many small companies have stopped their work in this area
and the pharmaceutical industry has also signiﬁcantly reduced
its antibiotic research and development programme. The de-
velopment of novel antibiotics and the evaluation of their
clinical application remains a major issue for the treatment of
infectious lung disease, such as that in CF.
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